268 results on '"Viret F"'
Search Results
2. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study
3. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
4. 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
5. LBA72 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
6. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
7. 343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial
8. Facteurs prédictifs de réponse à la radiochimiothérapie néoaduvante dans les cancers rectaux localement évolués et corrélation de ces facteurs avec la survie
9. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
10. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases
11. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol
12. Indications de la biopsie guidée par échoendoscopie dans les pathologies hépatiques
13. A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience
14. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment
15. Traitement précoce de l’anémie, en cours de chimiothérapie, par érythropoïétine : qu’attendre d’un schéma simplifié? À propos de l’expérience de l’Institut Paoli Calmettes-Marseille
16. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy
17. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†
18. Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study
19. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
20. Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involment
21. Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma?
22. Hépatectomie majeure pour métastases de cancers colorectaux chez le sujet âgé
23. Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation
24. Liver does not care about age
25. Transplantation of allogeneic CD34+ blood cells in leukemia or lymphoma patients at high risk of GVHD
26. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study
27. Highly emotionally loaded breaking bad news (BBN) scenarios: how to promote a Simulated Patients (SP) team’s motivation
28. Bevacizumab-Erlotinib As Maintenance Therapy in Metastatic Colorectal Cancer. Final Results of the Gercor Dream Study
29. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.
30. Two-stage hepatectomy: Who will not jump over the second hurdle?
31. FOLFIRI followed by radiochemotherapy and surgery in locally advanced gastric cancer: FFCD 0308 phase II trial.
32. BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
33. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response
34. Radio-chimiothérapie néo-adjuvante dans les cancers du rectum localement avancés : la « réponse tumorale » est-elle prévisible et pronostique ? (419)
35. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma
36. A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial
37. mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study
38. Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers
39. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial
40. CO.133 Association Cetuximab-FOLFIRI en traitement de 1re intention du cancer colorectal métastatique : données de survie et impact du statut KRas de l’étude CRYSTAL
41. CO.74 Phase II randomisée comparant une bithérapie standard à trois schémas de chimiothérapie intensifiée en première ligne de traitement des patients atteints de métastases hépatiques non résécables d’un cancer colorectal : METHEP
42. CO.75 Phase II multicentrique évaluant l’association de cetuximab au schéma FOLFIRINOX chez des patients traités en première ligne métastatique pour un cancer colorectal métastatique (CCRM) : résultats préliminaires
43. CO.56 Etude de phase II randomisée évaluant une radio-chimiothérapie par docetaxel-cisplatine en cas de cancer du pancréas localement avancé. Résultats préliminaires de l’essai ACCORD9/0201 du groupe digestif de la FNCLCC
44. CO.58 Chimiothérapie par gemcitabine et oxaliplatine (GEMOX) seule ou combinée au cetuximab bimensuel en première ligne de traitement des cancers biliaires avancés : résultats préliminaires de l’essai de phase II randomisé multicentrique franco-allemand BINGO
45. CO.117 Analyse intermédiaire planifiée de l’essai de phase III intergroupe FFCD-GERCOR-FNCLCC-AERO comparant deux séquences de chimiothérapie dans les cancers gastriques métastatiques ou localement avancés
46. Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
47. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)
48. Systematic versus on-request patients' access to medical files: Randomized trial—Influence on anxiety, quality of life and treatment satisfaction in cancer patients
49. Conservative Management of Squamous Cell Anal Carcinoma With External Beam Radiation Therapy and Low Dose 192Ir Interstitial Brachytherapy
50. O.9 Capecitabine (XELODA®, X) and oxaliplatine (ELOXATIN®, LOHP) regimen (XELOX) in elderly patients with metastatic colorectal cancer (MCRC): a FNCLCC French Collaborative Group GERICO 02 phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.